bucladesine has been researched along with rofecoxib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Amagase, K; Ashida, Y; Hatazawa, R; Kato, S; Takeuchi, K; Tanaka, A; Tanigami, M | 1 |
2 other study(ies) available for bucladesine and rofecoxib
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors.
Topics: Animals; Benzamides; Benzoates; Bucladesine; Colforsin; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprostone; Lactones; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Rats; Rats, Sprague-Dawley; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP4 Subtype; Stomach Ulcer; Sulfones; Vascular Endothelial Growth Factor A; Wound Healing | 2007 |